NCT06324240 2026-01-26Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast CancerEmory UniversityPhase 1 Recruiting18 enrolled
NCT03449108 2025-11-21LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasM.D. Anderson Cancer CenterPhase 2 Active not recruiting30 enrolled
NCT04954599 2025-10-07Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICIMaastricht University Medical CenterPhase 1/2 Recruiting126 enrolled
NCT03126110 2025-08-14Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Completed145 enrolled 47 charts